Article
10 questions pharma procurement teams should ask when evaluating commercialization partners
-
Hugo Pessoa, PharmD, MBA
How to distinguish service providers from strategic partners in complex post-launch environments
In post‑launch operations, biopharma procurement teams are under pressure to move quickly, often across multiple markets, functions, and stakeholders, without increasing risk. Speed alone, however, rarely protects the business.
Issues in commercialization rarely come down to partner availability or pricing. They emerge later, through weak governance, poor scalability, unclear accountability, and delivery models that do not integrate with how the organization actually operates.
That is why effective commercialization partner evaluation must go beyond service claims and rate cards. Procurement teams need to assess whether a partner can operate as a reliable extension of their global operating model, supporting speed where appropriate while strengthening control and reducing downstream risk.
The 10 questions below are designed to help surface those realities early, while key decisions are still reversible.
Issues in commercialization rarely come down to partner availability or pricing. They emerge later, through weak governance, poor scalability, unclear accountability, and delivery models that do not integrate with how the organization actually operates.
That is why effective commercialization partner evaluation must go beyond service claims and rate cards. Procurement teams need to assess whether a partner can operate as a reliable extension of their global operating model, supporting speed where appropriate while strengthening control and reducing downstream risk.
The 10 questions below are designed to help surface those realities early, while key decisions are still reversible.
1. What strategic problem are we solving, and is this vendor built to solve it with us?
Commercialization partner evaluations often start too far downstream, focusing on tasks, scope, or price before there is agreement on the business problem itself. Procurement’s first step should be to ensure there is a shared understanding of the strategic problem at hand, whether that is accelerating launch execution, stabilizing post launch operations, expanding into new markets, or reducing operational risk. Without that clarity, it is difficult to judge whether a partner is the right fit.
The strongest partners demonstrate they understand the trade‑offs procurement must manage, such as speed versus control and cost versus value. More importantly, they show a partnership posture by challenging assumptions, co‑designing solutions, and sharing accountability for outcomes, not just tasks.
The strongest partners demonstrate they understand the trade‑offs procurement must manage, such as speed versus control and cost versus value. More importantly, they show a partnership posture by challenging assumptions, co‑designing solutions, and sharing accountability for outcomes, not just tasks.
2. Can the vendor execute consistently across our operating footprint, including priority markets?
Commercialization rarely succeeds through fragmented delivery. A partner may have coverage in the right markets on paper, but that is not the same as delivering a coordinated model across those markets in practice.
Procurement should look for a coverage model that provides clarity on how work is divided between internal teams, local affiliates or in-market resources, and third parties, and how consistency is maintained across regions. The question is not simply whether a partner has a presence in priority markets, but whether they can deliver consistent standards, reporting, and governance while still enabling strong local execution.
Procurement should look for a coverage model that provides clarity on how work is divided between internal teams, local affiliates or in-market resources, and third parties, and how consistency is maintained across regions. The question is not simply whether a partner has a presence in priority markets, but whether they can deliver consistent standards, reporting, and governance while still enabling strong local execution.
3. How quickly can they become fully operational without relying on shortcuts?
Speed to becoming operational matters, whether the program supports an initial launch or a mature portfolio under pressure to deliver more efficiently. In both cases, fast starts that rely on informal workarounds or unclear ownership often create downstream issues.
Procurement should seek evidence of how a partner stands up delivery after signature, and expect defined onboarding plans with clear roles, timelines, dependencies, and decision points. The key question is not whether a partner can mobilize quickly once. It is whether they can do so in a structured, repeatable way that the business can trust.
Procurement should seek evidence of how a partner stands up delivery after signature, and expect defined onboarding plans with clear roles, timelines, dependencies, and decision points. The key question is not whether a partner can mobilize quickly once. It is whether they can do so in a structured, repeatable way that the business can trust.
4. How mature is their technology enablement, and does it improve control in addition to speed?
Technology capability is only valuable if it improves transparency and control. Procurement should assess whether digital tools meaningfully support workflow visibility, tracking, auditability, and reporting, or simply promise efficiency gains without enterprise integration.
Equally important is realism. Partners should demonstrate credible integration paths with existing systems and data, appropriate resourcing, and evidence of adoption at scale, not just pilot-level capability.
Equally important is realism. Partners should demonstrate credible integration paths with existing systems and data, appropriate resourcing, and evidence of adoption at scale, not just pilot-level capability.
5. Is the commercial model aligned to outcomes, including transparent pricing logic?
Procurement teams need pricing models they can explain, defend, and manage over time. That starts with clarity on cost drivers, visible assumptions, and a model that can absorb scope volatility, such as volume shifts, new markets, or new work types, without constant renegotiation.
A useful commercial model is not just competitively priced at the start. It remains workable as the business evolves, supported by governance mechanisms that enable forecasting, budget control, and corrective action, enabling procurement to manage spend proactively rather than reactively.
A useful commercial model is not just competitively priced at the start. It remains workable as the business evolves, supported by governance mechanisms that enable forecasting, budget control, and corrective action, enabling procurement to manage spend proactively rather than reactively.
6. How do they identify, prevent, and manage operational risk?
Risk management is central to vendor selection in commercialization. Beyond assurances, procurement should look for evidence of an inspection‑ready mindset, including disciplined standard operating procedures, documentation quality, training rigor, tested escalation procedures, and protection of operational continuity.
Preparedness shows up not only in delivery practices but also in contractual guardrails that protect the business and clarify responsibilities when issues arise.
Preparedness shows up not only in delivery practices but also in contractual guardrails that protect the business and clarify responsibilities when issues arise.
7. Can the vendor work within our governance model and flex to global and regional realities?
Vendors that impose a standard operating model often struggle in complex enterprises. Procurement should evaluate a partner’s ability to adapt governance to how the organization actually operates, balancing global oversight with regional execution pressures.
Clarity on decision rights, escalation paths, and operational cadence is essential to maintain speed without bypassing controls or stakeholders.
Clarity on decision rights, escalation paths, and operational cadence is essential to maintain speed without bypassing controls or stakeholders.
8. Can they create cross‑functional value beyond the initial scope without adding chaos?
Commercialization frequently breaks down at functional handoffs. Partners that can bridge silos across regulatory, pharmacovigilance, quality, and access functions help reduce execution risk.
Procurement should also seek evidence that a partner has a disciplined approach to identifying adjacent efficiencies and scaling responsibly, rather than expanding scope in ways that increase complexity or vendor sprawl.
Procurement should also seek evidence that a partner has a disciplined approach to identifying adjacent efficiencies and scaling responsibly, rather than expanding scope in ways that increase complexity or vendor sprawl.
9. What evidence supports their marketing claims, and how comparable is it to our environment?
Procurement credibility relies on evidence. Case examples should reflect comparable complexity, including similar markets, lifecycle stages, and risk profiles, backed by measurable outcomes such as timelines, quality improvements, risk reduction, or cost predictability.
Transparency around challenges and corrective actions often demonstrates greater operational maturity than presentations that show only flawless outcomes.
Transparency around challenges and corrective actions often demonstrates greater operational maturity than presentations that show only flawless outcomes.
10. Will this choice be defensible internally and aligned with the business unit that owns outcomes?
Ultimately, procurement must justify partner decisions to finance, legal, compliance, and business stakeholders. The strongest partner choices are those with clear success definitions, aligned incentives, and decision logic that stands up to scrutiny.
A good partner makes the decision easy to explain through clarity, controls, evidence, and accountability, reducing friction long after the contract is signed.
A good partner makes the decision easy to explain through clarity, controls, evidence, and accountability, reducing friction long after the contract is signed.
Conclusion
Effective vendor selection in commercialization is not defined by speed or headline pricing. It is defined by how well a partner aligns with the enterprise operating model, governance expectations, and long‑term objectives of the business.
By asking better questions early, procurement teams can surface execution risk sooner, assess strategic fit more objectively, and shape decisions that remain defensible over time. Used consistently, this framework helps shift conversations from vendor comparison to partnership design, strengthening control, protecting value, and supporting sustainable delivery at scale.
Contact us to explore how these questions apply to your commercialization programs and operating model.
By asking better questions early, procurement teams can surface execution risk sooner, assess strategic fit more objectively, and shape decisions that remain defensible over time. Used consistently, this framework helps shift conversations from vendor comparison to partnership design, strengthening control, protecting value, and supporting sustainable delivery at scale.
Contact us to explore how these questions apply to your commercialization programs and operating model.
About the author:
Hugo Pessoa, PharmD, MBA is Senior Director, Global Consulting Services – Global Strategic Accounts at Cencora. A senior commercial leader in pharmaceutical and biotech consulting, he partners with complex global organizations to drive growth across the full product lifecycle—from clinical development and regulatory strategy through pharmacovigilance, market access, and commercialization. Hugo specializes in building long term strategic relationships, guiding transformation in multinational environments, and delivering scalable, outcome driven solutions for global life sciences leaders.
Avis de non-responsabilité :
Les renseignements fournis dans cet article ne constituent pas des conseils juridiques. Cencora, Inc. encourage fortement les lecteurs à consulter les informations disponibles sur les sujets abordés et à se fier à leur propre expérience et expertise pour prendre des décisions à cet égard.
Entrez en contact avec notre équipe
Notre équipe d’experts de la valeur se consacre à la transformation des données probantes, des informations sur les politiques et des renseignements sur le marché en stratégies efficaces d’accès au marché mondial. Laissez-nous vous aider à naviguer dans le paysage complexe des soins de santé d’aujourd’hui en toute confiance. Contactez-nous pour découvrir comment nous pouvons vous aider à atteindre vos objectifs.
